HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) CME: Take the course for this article: Volume 66, Number 8, April 25, 2006 Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in Neurology Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Qureshi, A. I. Articles by Divani, A. A. Search for Related Content PubMed PubMed Citation Articles by Qureshi, A. I. Articles by Divani, A. A. Related Collections MRI All Cerebrovascular disease/Stroke Infarction All Clinical trials Clinical trials Observational study (Cohort, Case control)

Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign?

From Clinical Trials Division, Zeenat Qureshi Stroke Research Center, Department of Neurology and Neurosciences, University of Medicine and Dentistry of New Jersey, Newark.

Address correspondence and reprint requests to Dr. Adnan I. Qureshi, 90 Bergen Street, DOC–8100, Newark, NJ 07103; e-mail: aiqureshi{at}hotmail.com

Objective: To evaluate the effect of IV recombinant tissue plasminogen activator (rt-PA) in patients with hyperdense artery sign (HAS) on initial CT scan.

Methods: The authors determined the differential effect of IV rt-PA (0.9 mg/kg) in patients with HAS by testing the interaction of rt-PA and HAS in a logistic regression model after adjusting for age, sex, initial NIH Stroke Scale score (NIHSSS), time to randomization, systolic blood pressure, serum glucose, body temperature, and rt-PA in 616 patients treated within 3 hours of symptom onset. Outcomes evaluated included intracranial hemorrhage, modified Rankin scale (mRS) 0–1, Barthel Index (BI) of 95, Glasgow Outcome Scale (GOS) of 0–1, NIHSSS 0–1, and death at 90 days.

Results: HAS was detected on the initial CT scan in 91 (15%) of the 616 patients by an independent neuroradiologist. Significantly lower rates of mRS 0–1, BI 95, GOS of 0–1, or NIHSSS 0–1 at 90 days were observed among patients with HAS. IV rt-PA significantly increased the rates of mRS 0–1, BI 95, GOS of 0–1, or NIHSSS 0–1 at 90 days after adjusting for potential confounders without any significant modifying effect (interaction) of HAS. Among the 91 patients with HAS, rt-PA use demonstrated a trend or significance for increased adjusted rates of favorable outcomes by mRS (p = 0.04), BI (p = 0.1), GOS (p = 0.03), and NIHSSS (p = 0.01).

Conclusion: Although hyperdense artery sign is associated with poor outcome, IV recombinant tissue plasminogen activator may be beneficial in this subgroup of patients with ischemic stroke.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the April 25 issue to find the title link for this article.

Disclosure: The authors report no conflicts of interest.

Received September 12, 2005. Accepted in final form January 3, 2006.

Related articles in Neurology:

April 25 Highlights

Neurology 2006 66: 1136-1137. [Full Text]  

This article has been cited by other articles:

				O. Ozdemir, A. Leung, M. Bussiere, V. Hachinski, and D. Pelz Hyperdense Internal Carotid Artery Sign: A CT Sign of Acute Ischemia Stroke, July 1, 2008; 39(7): 2011 - 2016. [Abstract] [Full Text] [PDF]

				H. P. Mattle, M. Arnold, D. Georgiadis, C. Baumann, K. Nedeltchev, D. Benninger, L. Remonda, C. von Budingen, A. Diana, A. Pangalu, et al. Comparison of Intraarterial and Intravenous Thrombolysis for Ischemic Stroke With Hyperdense Middle Cerebral Artery Sign Stroke, February 1, 2008; 39(2): 379 - 383. [Abstract] [Full Text] [PDF]